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Abstract
The relatively new anti-cancer drug, crizotinib (Xalkori®,
Pfizer), has created excitement in the research community.
This drug has exhibited dramatic clinical benefits for select
non-small cell lung cancer patients showing evidence of a
mutation in the EML4-ALK gene. This gene mutation is present in 4 to 5 percent of non-small cell lung cancer patients.
Crizotinib acts through a tyrosine kinase inhibition pathway,
targeting the ALK and MET tyrosine kinases, to inhibit phosphorylation of activated ALK, which halts the ALK gene mutation and impedes metastasis. In phase I clinical trials, a 57
percent overall response rate was shown, and researchers
calculated that the six-month progression-free survival was
72 percent.1 Therefore, patients treated with crizotinib had
an increased survival rate when compared to conventional
chemotherapy. Although the success rate of crizotinib is high,
the mutated ALK gene has been shown to develop resistance
to it. However, the predicted impact of this drug is still promising.
Background
Lung cancer is the leading cause of cancer-related death in
the United States, with a five-year survival rate of approximately 15.6 percent.2 The World Health Organization divides
lung cancer into two major classes based on biology, therapy,
and prognosis: non-small cell lung cancer (NSCLC) and smallcell lung cancer (SCLC).2 NSCLC accounts for more than 85
percent of lung cancer cases and presents as either a locally
advanced or metastatic disease.3 Recently, malignancies have
been attributed to genetic alterations in a single gene causing
the cancer to become reliant on signaling from the encoded
protein, usually a receptor tyrosine kinase. 4 Therefore, current treatments for NSCLC have focused on the use of targeted drug therapy, namely the epidermal growth factor receptor (EGFR) inhibitors, gefitinib and erlotinib, and the vascular endothelial growth factor (VEGF) inhibitor, bevacizumab. Recently, a new type of targeted drug therapy for
NSCLC has emerged. This therapy targets mutations of the
anaplastic lymphoma kinase (ALK) and the echinoderm
microtubule-associated protein-like 4 (EML4) genes. Crizotinib (Xalkori®) is an inhibitor of ALK and MET tyrosine
kinases, allowing for effective control of the disease state.2
Mutation of the ALK Gene, Prevalence, and Testing
The EML4-ALK mutation was first discovered in 1997 from a
lung adenocarcinoma.3 This mutation is a fusion-type protein
tyrosine kinase that is present in 4 to 5 percent of NSCLC
cases.s Of these cases, a total of approximately 10,000 patients within the United States are affected each year,2.3 The
EML4-ALK fusion gene is more prevalent in nonsmokers, in
patients with a history of light smoking and in patients with
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adenocarcinomas. Therefore, evidence suggests that the ALK
gene rearrangement is a distinct subgroup of lung cancer
that is not related to smoking. Additionally, patients with the
EML4-ALK gene are typically younger than the average
NSCLC patient.4 While genetic alterations involving ALK have
been identified in other malignancies, the EML4-ALK fusion
is unique to NSCLC. The EML4-ALK mutation is produced as
the result of a small inversion within the short arm of human
chromosome 11. 5 ALK undergoes dimerization through interaction within the coiled-coil domain at the EML4 regions of
each monomer, activating ALK.S Activated ALK is involved in
the promotion of cellular growth and the inhibition of apoptosis, generating oncogenic activity.3
Before the FDA approved crizotinib, the Vysis ALK Break
Apart Fluorescent in situ hybridization (FISH) Probe Kit detected chromosomal rearrangements in the ALK gene. This
test utilizes fluorescent-labeled DNA probes to indicate the
existence of the ALK gene chromosomal rearrangement
found via lung biopsy. If the test is positive for an ALK gene
rearrangement, the patient may benefit from crizotinib treatment.6 A limitation of the Vysis ALK Break Apart FISH
method is the detection of only ALK gene rearrangements
versus identification of actual EML4-ALK fusion genes. Some
other diagnostic methods for the EML4-ALK gene mutation
are immunohistochemistry (IHC) and reverse transcriptase
polymerase chain reaction (RT-PCR), but the Vysis ALK
Break Apart FISH method is most widely used.
Crizotinib and Clinical Trials
As an oral receptor tyrosine kinase inhibitor, crizotinib is
used in the treatment of locally advanced and metastatic
NSCLC. Crizotinib inhibits ALK and Hepatocyte Growth Factor Receptor (HGFR, c-Met) tyrosine kinases by preventing
their phosphorylation and halting tumor cell growth. 1,s The
recommended dosing of crizotinib is 250 mg twice daily
taken with or without food.7
In the phase I trial conducted by Kwak et al., the efficacy and
adverse events of crizotinib were tested in an expanded cohort study. Eighty-two patients with ALK-rearranged advanced NSCLC cancer participated in the trial. The subjects
were tested for ALK-gene rearrangements using the FISH
method. FISH positive samples had split ALK 5' and 3' DNA
probe signals or single 3' signals in more than 15 percent of
the tumor cells. For evaluation, patients had a baseline tumor
assessment, received a dose of oral crizotinib on day one of
the first 28-day cycle, and then completed a minimum of one
post-baseline tumor assessment. Patients received 250 mg of
crizotinib twice daily. Patient safety was monitored every
two weeks during the first two cycles and every four weeks
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afterward. Progression-free survival was calculated from the
date crizotinib was first administered to the date of disease
progression or death from any cause. There was a 57 percent
(95 % CI, 46 to 68) overall response rate defined as confirmed partial or complete response. An additional 33 percent met the standards for stable disease. The most common
side effects reported were grade one nausea and diarrhea.
Forty-one percent of patients reported mild visual disturbances described as moving trails of light, but this improved
over time. At trial completion, 77 percent of the patients continued on crizotinib therapy. The average treatment duration
was 6.4 months with ongoing follow-up, and the six-month
progression-free survival was 72 percent (95% CI, 61 to 83).
Therefore, patients with ALK-positive NSCLC who are treated
with crizotinib have an increased survival rate compared to
those patients treated with standard chemotherapy.1
The use of crizotinib was also tested in two multi-center, single-arm studies investigating the treatment of locally advanced or metastatic ALK-positive NSCLC. In study A, participants were tested for ALK-gene rearrangements using the
FISH method. Study B identified ALK-gene rearrangements
using local clinical trial assays. Objective response rate (ORR)
according to Response Evaluation Criteria in Solid Tumors
(RECIST) was the primary endpoint in both trials and was
interpreted by an investigator and an independent radiology
review panel. A secondary endpoint was duration of response (DR).7Trial A consisted of 136 patients who were
analyzed at data cutoff. The median 22-week trial duration
produced an ORR of 50 percent (95% CI, 42 to 52) with one
complete and 67 partial responses. The first eight weeks of
treatment provided 79 percent of objective tumor responses.
The median response duration was 41.9 weeks. Trial B assessed 119 patients for a median treatment duration of 32
weeks. Two complete and 69 partial responses were identified, with an ORR of 61 percent (95% CI, 52 to 70). The first
eight weeks of treatment provided 55 percent of objective
tumor responses. The median response duration was 48.1
weeks. 7Phase III trials assessing the use of crizotinib versus
the current standards of care are ongoing, with study completions expected in September 2012 and October 2013.
The majority of side effects related to crizotinib were ophthalmic in nature and usually not life-threatening, but crizotinib does have some adverse reactions that are potentially
very serious and require monitoring by health care professionals. These adverse effects of crizotinib included visual
impairment, photopsia, blurred vision, vitreous floaters, photophobia, and diplopia in 62 percent of patients during the
first two weeks of crizotinib administration. Neuropathy,
bradycardia, and complex renal cysts have also been observed. Crizotinib has the potential to cause life-threatening
pneumonitis; therefore, patients should be monitored for
symptoms of pneumonitis while taking crizotinib. This drug
has also been associated with QT interval prolongation and
should be avoided in patients with congenital long QT syndrome and should not be combined with drugs that may prolong the QT interval such as clarithromycin, moxifloxacin,
amiodarone, sotalol, procainamide or quinidine. Patients
suffering from congestive heart failure, bradyarrhythmias,
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electrolyte irregularities and those patients taking medications that prolong the QT interval should be monitored.
Crizotinib is a CYP3A4 inhibitor. Common drug interactions
with crizotinib include drugs that alter crizotinib plasma
concentrations, such as other CYP3A4 inhibitors
(clarithromycin and ketoconazole) and CYP3A4 inducers
(phenytoin and carbamazepine), and their concomitant use
should be monitored. Crizotinib's absorption is pH dependent, and drugs increasing gastric pH reduce its solubility and
bioavailability. Crizotinib is classified as a pregnancy
category D drug and should be avoided unless benefit
substantially outweighs the risk.7

Resistance to crizotinib
Despite crizotinib's effectiveness in patients with EML4-ALK
gene fusions, the cancer usually becomes resistant within the
first year. According to Katayama et al., a patient who became resistant to crizotinib after five months of treatment
was found to have two common secondary mutations in the
kinase domain of the EML4-ALK gene, C1156Y, and a gatekeeper mutation, L1196M. These mutations are also resistant
to other more potent ALK tyrosine kinases. When tumors
show secondary mutations in the kinase domain of a gene,
drug resistance is common. Other methods of drug resistance
include amplification of the gene targeted by the kinase or
activation of a different signaling mechanism bypassing the
kinase activation. Due to these genetic mutations conferring
drug resistance, new drugs are being developed to help treat
patients who acquire tyrosine kinase inhibitor resistance.9
Conclusion
Lung cancer continues to be one of the leading causes of cancer-related death, with NSCLC affecting the majority of patients. The discovery of the EML4-ALK gene mutation and
crizotinib's ability to target this gene offers another treatment option. More research, as well as advancing technologies in targeted drug therapy, shows promise in the development of future cancer drug therapies. With this knowledge,
researchers are able to learn more about cancer pathogenesis, targeted drug therapy and drug resistance with the ultimate goal of improving patient outcomes.
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